Corvus Pharmaceuticals, Inc. (CRVS)
| Market Cap | 1.32B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -15.28M |
| Shares Out | 83.99M |
| EPS (ttm) | -0.53 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 870,468 |
| Open | 15.85 |
| Previous Close | 15.92 |
| Day's Range | 15.50 - 16.31 |
| 52-Week Range | 3.17 - 26.95 |
| Beta | 0.97 |
| Analysts | Strong Buy |
| Price Target | 30.17 (+91.8%) |
| Earnings Date | May 7, 2026 |
About CRVS
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company’s lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferat... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for CRVS stock is "Strong Buy." The 12-month stock price target is $30.17, which is an increase of 91.80% from the latest price.
News
Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D.
SOUTH SAN FRANCISCO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, announced today that Andrew C. Chan, M.D., Ph.D...
Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting
Two oral presentations including late-breaker at SID Data will cover Phase 1 clinical trial of soquelitinib for atopic dermatitis, including new immunologic and biomarker data supporting drug-free re...
Corvus Pharmaceuticals Earnings Call Transcript: Q4 2025
Soquelitinib showed strong efficacy and durable responses in atopic dermatitis and PTCL, with robust safety and broad applicability. Financial position is solid after a $200M financing, supporting an expanded clinical pipeline and cash runway into 2028.
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in patients who have received prior systemic therapy
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
Corvus Pharmaceuticals Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Soquelitinib, a selective oral ITK inhibitor, demonstrated strong efficacy and durable responses in atopic dermatitis, including in patients resistant to prior therapies, with a favorable safety profile. Large market opportunities exist, and multiple phase II and III trials are planned through 2026.
Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership t...
Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M
SOUTH SAN FRANCISCO, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the closing of an upsized underw...
Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the pricing of an upsized underw...
Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwr...
What made Corvus stock double on Tuesday and is it sustainable?
Corvus Pharmaceuticals (NASDAQ: CRVS) shares more than doubled on Jan. 20 after announcing positive Phase 1 trial data for “soquelitinib” – its oral investigational drug for atopic dermatitis. Soqueli...
Corvus Stock Spikes On Heels Of Strong Eczema Study Results
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) on Tuesday shared data from cohort 4 of the Phase 1 trial evaluating soquelitinib in patients with moderate-to-severe atopic dermatitis.
Corvus Pharmaceuticals Transcript: Study result
Phase I results for Soquelitinib in atopic dermatitis show strong efficacy, durable responses, and a favorable safety profile, including in patients with prior systemic therapy. The drug’s novel mechanism induces Tregs and reduces key cytokines, supporting broad potential in immune diseases. Phase II trials in AD, asthma, and HS are planned.
Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Company to host conference call and webcast on Tuesday, January 20, 2026 at 8:00 am ET / 5:00 am PT Company to host conference call and webcast on Tuesday, January 20, 2026 at 8:00 am ET / 5:00 am PT
Corvus Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Soquelitinib is advancing in both oncology and atopic dermatitis, with strong early safety and efficacy data and a pivotal phase II AD trial set to begin. The program is differentiated by its oral administration and biomarker-driven approach, with significant commercial potential and a solid cash runway.
Corvus Pharmaceuticals Earnings Call Transcript: Q3 2025
Soquelitinib advanced in atopic dermatitis and T-cell lymphoma, with strong phase I data and phase II trial set for early 2026. Cash reserves support operations into late 2026, and expansion into new indications and potential partnerships are planned.
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results
Completed enrollment in soquelitinib atopic dermatitis Phase 1 trial extension cohort 4 (200 mg BID dose with 8-week treatment period) with data announcement anticipated in January Soquelitinib atopic...
Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership t...
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025
Trial is evaluating ciforadenant as a potential first line therapy for metastatic renal cell cancer (RCC) in combination with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1)
Corvus Pharmaceuticals Appoints David Moore to Board of Directors
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced today that David Moore, Executive Vice...
Corvus Pharmaceuticals Earnings Call Transcript: Q2 2025
Socolitinib showed strong efficacy and safety in atopic dermatitis, with a phase II trial set to start by year-end and results expected in about 18 months. Cash position improved to $74.4 million, funding operations into Q4 2026, while multiple clinical programs advance on schedule.
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results
Soquelitinib data from cohort 3 of atopic dermatitis Phase 1 clinical trial demonstrates earlier and deeper responses compared to cohorts 1-2 along with clinically meaningful reduction in itch as earl...
Corvus Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025
Soquelitinib, a highly selective ITK inhibitor, demonstrated strong efficacy and safety in phase one atopic dermatitis trials and is advancing in phase three for lymphoma. The drug targets multiple cytokines, offering broad potential in immune and oncology markets, with key extension data expected in Q4.
Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Cohort 3 demonstrates earlier and deeper responses compared to cohorts 1-2 All three cohorts show separation from placebo with statistically significant difference from placebo at day 28 Cohort 3 demo...